Document:

DC7751.pdf -- Converted by SEC Publisher 4.2, created by BCL Technologies Inc., for SEC Filing

	
TERMINATION AGREEMENT

     THIS TERMINATION AGREEMENT (this “Agreement”), dated November 10, 2009 (the “Termination Date”) is between:

     Angiotech Pharmaceuticals, Inc., a company organized and existing under the laws of British Columbia, Canada, with an office at 1618 Station Street, Vancouver, BC,
Canada V6A 1B6 (“Angiotech”); and

     CombinatoRx Incorporated, a company organized and existing under the laws of Delaware, with an office at 245 First Street, Cambridge, MA 02142
(“CombinatoRx”).

     WHEREAS, Angiotech and CombinatoRx are parties to a Research and License Agreement, dated October 3, 2005 (the “Research and License Agreement”) pursuant to which CombinatoRx has performed
certain research activities for Angiotech during the Research Period (as defined in the Research and License Agreement); 

     WHEREAS, the Research Period initially ran until April 30, 2008, but was extended by Angiotech to October 3, 2010 upon payment to CombinatoRx of an additional $7,000,000; 

     WHEREAS, the Angiotech and CombinatoRx have determined that it is in their best interests to mutually terminate the Research and License Agreement under the terms and conditions of this
Agreement;

     NOW, THEREFORE, in consideration of the promises and mutual covenants and other good and valuable consideration hereinafter set forth, the receipt and sufficiency of which is hereby acknowledged,
Angiotech and CombinatoRx (individually referred to as “Party” and collectively as “Parties”) hereby agree as follows:

	
(1)      		
Termination of Research and License Agreement. Effective as of the Termination Date, the Research and License Agreement shall terminate and shall have no further force or effect, nor ongoing
obligations, subject to survival of certain provisions as set forth in Article 2 hereof.	
	 
	
(2)      		
Consequences of Termination.	
	 
	 	
(a)      		
Return of Material; Termination of Rights. Except as set forth in Section 2(b) below, all rights and licenses granted by one Party to the other Party, and all obligations of one Party to the other
Party, under the Research and License Agreement shall terminate, and each Party shall return all data, files, records and other materials in its possession or control containing or comprising the other Party’s Information, or other Confidential
Information (each as defined in the Research and License Agreement) to which such first Party does not retain rights under the Research and License Agreement or this Agreement (except one copy of which may be retained by the returning Party solely
for archival purposes). For the avoidance of doubt, Section 15.9 of the Research and License Agreement shall be of no further force or effect.	
	 

1

	 	
(b)      		
Surviving Obligations. Article 10 and the rights and obligations of the Parties thereunder shall survive the termination of the Research and License Agreement by this Agreement. For the avoidance
of doubt, Section 15.10 of the Research and License Agreement shall be of no further force or effect.	
	 
	 	
(c)      		
Other Matters. For purpose solely of clarity, CombinatoRx shall not be required to refund to Angiotech any funds paid to CombinatoRx under the Research and License Agreement. Angiotech shall own
all right, title and interest to any and all intellectual property which has already been transferred to it in accordance with the terms of the Research and License Agreement.	
	 
	
(3)      		
Mutual Release. Each of Angiotech and CombinatoRx, in consideration of the agreements hereunder and for other valuable consideration, the receipt and sufficiency of which are acknowledged,
for themselves, and for their respective subsidiaries, affiliates, agents, directors, officers, employees, successors, attorneys and assigns (“Angiotech Releasors” and “CombinatoRx Releasors,” respectively) fully releases and
discharges, and covenants not to sue, the other Party, its present and former subsidiaries, affiliates, directors, officers, employees, agents, stockholders, successors, attorneys and assigns, forever, from and with respect to any claims,
liabilities, actions and suits of any nature, whether in law, at equity or otherwise, which the Angiotech Releasors and the CombinatoRx Releasors ever had or now have upon, or by reason of any matter, cause or thing whatsoever from the beginning of
the world to the Termination Date that relates to or arises from the Research and License Agreement or its termination; provided that the foregoing shall not relieve either Party of its obligations under this Agreement.	
	 
	
(4)      		
Entire Agreement; Modifications; Waiver. This Agreement (together with the Research and License Agreement) fully expresses the entire understanding between the Parties, and supersedes any
prior agreements, understandings, or discussions between the Parties. It may not be hereafter added to, altered, or modified except by written instrument signed by both Parties. No delay, or omission in the exercise of any right, power, or remedy
hereunder by either Party shall impair such right, power, or remedy or be considered to be a waiver of any default or acquiescence therein by such Party.	
	 
	
(5)      		
Severability. In the event that any provision of this Agreement is determined to be invalid or unenforceable by a court of competent jurisdiction, the remainder of this Agreement shall
remain in full force and effect without said provision. In such event, the Parties shall in good faith attempt to negotiate a substitute clause for any provision declared invalid or unenforceable, which substitute clause shall most nearly
approximate the intent of the Parties in agreeing to such invalid provision, without itself being invalid.	
	 
	
(6)      		
Governing Law; Arbitration. This Agreement shall be governed, interpreted and construed in accordance with the substantive laws of the State of New York, without regard to conflict of laws
principles thereof. Any dispute, controversy or claim arising under, out of, in connection with or in relation to this Agreement, or the breach, termination, validity or enforceability of any provision hereof, will be resolved as set forth in
Article 16 of the Research and License Agreement.	
	 

2

	
(7)      		
Binding on Successors and Assigns. This Agreement is binding upon each Party, and shall inure to the benefit of each Party to this Agreement and their respective officers, directors,
investors, employees, counsel, agents, subsidiaries, parent corporations, affiliated companies, predecessors, successors, assigns, agents, heirs, and personal representatives.	
	 
	
(8)      		
Joint Drafting. For purposes of construction, this Agreement shall not be deemed to have been drafted by any Party, and any ambiguity shall not be construed against any Party.	
	 
	
(9)      		
Execution; Execution in Counterpart. Each Party represents and warrants that it has full power and authority to enter into this Agreement and without conflict with any other agreement or
obligation of such Party. This Agreement may be executed in counterpart by the Parties, either through original copies or by facsimile or electronic copies. An executed copy of this Agreement delivered by facsimile or electronically will constitute
valid execution and delivery of this Agreement.	
	 

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly authorized representatives, effective as of the Termination Date.

	
Angiotech Pharmaceuticals, Inc. 
		
 		
CombinatoRx, Incorporated 
	
	
 
	
	
/s/ David D. McMasters 
		
 		
/s/ Jason F. Cole 
	
	

		
		

	
	
Signature 
		
 		
Signature 
	
	
David D. McMasters 
		
 		
Jason F. Cole 
	
	

		
		

	
	
Printed Name 
		
 		
Printed Name 
	
	
General Counsel 
		
 		
SVP & General Counsel 
	
	

		
		

	
	
Title 
		
 		
Title 
	

3First Supplemental Indenture

 Exhibit 4.1 
 FIRST SUPPLEMENTAL INDENTURE 
 FIRST
SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”), dated as of November 9, 2009, by and among JohnsonDiversey, Inc., a Delaware corporation (the “Company”), the
Guarantors (as defined in the Indenture referred to below) and The Bank of New York Mellon (as successor to The Bank of New York), a New York banking corporation, as trustee under the Indenture referred to below (the “Trustee”).
Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture. 
 W I T N E S S E T
H 
 WHEREAS, the Company and the Guarantors have heretofore executed and delivered to the Trustee an indenture, dated as of
May 3, 2002, by and among the Company, the guarantors named therein, and the Trustee (as amended, supplemented or otherwise modified from time to time, the “Indenture”), providing for the issuance of (and pursuant to which the
Company has issued) €225,000,000 aggregate principal amount of the Company’s Series A and Series B 9.625% Senior Subordinated Notes due 2012 (the “Notes”); 
 WHEREAS, on October 7, 2009, (i) JohnsonDiversey Holdings, Inc., a Delaware corporation and the Company’s parent
(“Holdings”), entered into an investment and recapitalization agreement (as amended or supplemented from time to time, the “Investment Agreement”), by and among Holdings, CDR Jaguar Investor Company LLC
(“CD&R Investor”), a Delaware limited liability company organized by Clayton, Dubilier & Rice Fund VIII, L.P., a private investment fund managed by Clayton, Dubilier & Rice, Inc., SNW Co., Inc.
(“SNW”), a Delaware corporation and a wholly-owned subsidiary of S.C. Johnson & Son, Inc. (“SCJ”), and Commercial Markets Holdco, Inc., a Wisconsin corporation (“CMH”), and (ii) the
Company and Holdings entered into a redemption agreement (as amended or supplemented from time to time, the “Redemption Agreement”), by and among the Company, Holdings, CMH, Unilever N.V. (“Unilever”), Marga B.V.,
an indirect wholly-owned subsidiary of Unilever (“Marga”), and Conopco, Inc. (“Conopco”); 
 WHEREAS, pursuant to the terms of the Investment Agreement, Holdings has agreed to use its reasonable best efforts to arrange and obtain debt financing (the “Financing”) consisting of at least $1.41 billion (less certain
existing debt that is not refinanced) and a revolving credit facility of at least $250 million on terms and conditions acceptable to each of CD&R Investor, CMH and Holdings in its reasonable judgment (acting in good faith); 
 WHEREAS, the Company has (i) offered to purchase for cash any and all of the outstanding Notes (the “Tender Offer”)
and (ii) requested that Holders of the Notes deliver their consents (the “Consents”) to eliminate certain restrictive covenants, certain events of default and substantially all of the restrictions on the ability of the Company
to merge, consolidate or sell all or substantially all of its properties or assets, and to waive any and all defaults that may have resulted in connection with, or may result from and after the consummation of, the transactions contemplated by the
Investment Agreement and the Redemption Agreement (collectively, the “Transactions”) or the Financing (the “Consent Solicitation”), in each case pursuant to the Offer to Purchase and Consent Solicitation Statement
dated as of October 26, 2009 (the “Offer to Purchase”); 

 WHEREAS, Section 9.02 of the Indenture provides that the Company and the Trustee may
amend or supplement the Indenture, the Subsidiary Guarantees and the Notes, with the consent of the Holders of at least a majority in principal amount of the then-outstanding Notes voting as a single class, and that, subject to Sections 6.04 and
6.07 of the Indenture, any existing Default or Event of Default (other than a Default or Event of Default in the payment of the principal of, premium or Special Interest, if any, or interest on the Notes, except a payment default resulting from an
acceleration that has been rescinded) or compliance with any provision of the Indenture, the Subsidiary Guarantees or the Notes may be waived with the consent of the Holders of a majority in principal amount of the then-outstanding Notes voting as a
single class; 
 WHEREAS, pursuant to the Consent Solicitation by the Company, Holders of at least a majority in aggregate
principal amount of the Notes have duly consented to the proposed amendments and waivers set forth in this First Supplemental Indenture in accordance with Section 9.02 of the Indenture; 
 WHEREAS, the Company has furnished, or caused to be furnished, to the Trustee, and the Trustee has received, (i) a copy of the
resolutions of the Board of Directors of the Company authorizing the execution of this First Supplemental Indenture, (ii) evidence of the written consent of the Holders set forth in the immediately preceding paragraph and (iii) an
Officers’ Certificate and an Opinion of Counsel described in Sections 13.04 and 13.05 of the Indenture; 
 WHEREAS, all
conditions necessary to authorize the execution and delivery of this First Supplemental Indenture have been complied with or have been done or performed; and 
 WHEREAS, this First Supplemental Indenture is effective as of the date upon which the conditions set forth in Section 3.01 hereof are satisfied, and the amendments and waivers effected by this First
Supplemental Indenture shall become operative with respect to the Notes at the Payment Date (as defined herein); 
 NOW,
THEREFORE, the Company and the Guarantors hereby covenant and agree with the Trustee for the equal and proportionate benefit of the Holders as follows: 
 ARTICLE 1 
 AMENDMENTS 
 Section 1.01 Amendments 
 (a) Amendment of Article 4. Subject to Section 3.01 hereof, the Indenture is hereby amended by deleting the following Sections of Article 4 of the Indenture and all references thereto: 4.03,
4.04, 4.05, 4.06, 4.07, 4.08, 4.09, 4.10, 4.11, 4.12, 4.13, 4.14, 4.15, 4.16, 4.17 and 4.18, in each case in its entirety, and replacing each such Section with the following: “Intentionally omitted.” 
 (b) Amendment of Article 5. Subject to Section 3.01 hereof, the Indenture is hereby amended by deleting the
following Sections of Article 5 of the Indenture and all references thereto: 5.01 and 5.02, in each case in its entirety, and replacing each such Section with the following: “Intentionally omitted.” 
  

 2 

 (c) Amendment of Section 6.01. Subject to Section 3.01
hereof, Section 6.01 of Article 6 of the Indenture is hereby amended by deleting the section in its entirety, together with any references to subsections thereof in the Indenture that, as provided below, are being replaced with the words
“intentionally omitted,” and replacing such Section 6.01 with the following: 
 “Each of the following is
an “Event of Default”: 
 (1) the Company defaults for 30 days in the payment when due of interest on,
or Special Interest with respect to, the Notes whether or not prohibited by the subordination provisions of this Indenture; 
 (2) the Company defaults in the payment when due (at maturity, upon redemption or otherwise) of the principal of, or premium, if any, on the Notes, whether or not prohibited by the subordination
provisions of this Indenture; 
 (3) intentionally omitted; 
 (4) failure by the Company or any of its Restricted Subsidiaries for 60 days after notice to comply with any of the other
agreements in this Indenture or the Notes; 
 (5) intentionally omitted; 
 (6) intentionally omitted; 
 (7) the Company pursuant to or within the meaning of Bankruptcy Law: 
 (A) commences a voluntary case, 
 (B) consents to the entry of an order for relief against it in an
involuntary case, 
 (C) consents to the appointment of a custodian of it or for all or substantially all of its
property, 
 (D) makes a general assignment for the benefit of its creditors, or 
 (E) generally is not paying its debts as they become due; or 
 (8) a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that: 
 (A) is for relief against the Company in an involuntary case; 
  

 3 

 (B) appoints a custodian of the Company or for all or substantially all of
the property of the Company; or 
 (C) orders the liquidation of the Company; 
 and the order or decree remains unstayed and in effect for 60 consecutive days. 
 (9) intentionally omitted.” 
 Section 1.02 Amendment of Definitions. Subject to Section 3.01 hereof, any defined terms present in the Indenture or the Notes but no longer used as a result of the amendments made by
this First Supplemental Indenture are hereby eliminated. The definition of any defined term used in the Indenture or the Notes where such definition is set forth in any of the sections or subsections that are eliminated by this First Supplemental
Indenture and the term it defines is still used in the Indenture or the Notes after the amendments hereby become operative shall be deemed to become part of, and defined in, Section 1.01 of the Indenture. Such defined terms are to be in
alphanumeric order within Section 1.01 of the Indenture. 
 ARTICLE 2 
 WAIVERS 
 Section 2.01 Waiver of Defaults. Any and all Defaults, Events of Default or other defaults, except a continuing Default or Event of Default in the payment of the principal of, premium or Special Interest, if any, or interest on
the Notes, that may have resulted in connection with, or may result from and after the consummation of, the Transactions or the Financing are hereby irrevocably waived. 
 ARTICLE 3 
 MISCELLANEOUS 
 Section 3.01 Effect and Operation of First Supplemental Indenture. This First Supplemental Indenture shall be effective and
binding immediately upon its execution by the Company, the Guarantors and the Trustee, and thereupon this First Supplemental Indenture shall form a part of the Indenture for all purposes, and every Note and Guarantee heretofore or hereafter
authenticated and delivered under the Indenture shall be bound hereby; provided however, notwithstanding anything in the Indenture or this First Supplemental Indenture to the contrary, the amendments and waivers set forth in Sections 1.01,
1.02 and 2.01 of this First Supplemental Indenture shall become operative only upon and simultaneously with, and shall have no force and effect prior to, the Company’s payment for Notes validly tendered (and not validly withdrawn) pursuant to
the Tender Offer, which payment occurs in connection with the closing of the Transactions (such date of payment, the “Payment Date”). If the Tender Offer is terminated or withdrawn, or the Company does not accept for purchase, and
pay for, the Notes for any reason, this First Supplemental Indenture shall not become operative. Except as modified and amended by this First Supplemental Indenture, all provisions of the Indenture shall remain in full force and effect. 

 

 4 

 Section 3.02 Indenture and First Supplemental Indenture Construed Together. This
First Supplemental Indenture is an indenture supplemental to, and in implementation of, the Indenture, and the Indenture and this First Supplemental Indenture shall henceforth be read and construed together. 
 Section 3.03 Trust Indenture Act Controls. If any provision of the Indenture, as amended by this First Supplemental Indenture,
limits, qualifies or conflicts with the duties imposed by TIA § 318(c), the imposed duties shall control. 
 Section 3.04 GOVERNING LAW. THE INTERNAL LAW OF THE STATE OF NEW YORK SHALL GOVERN AND BE USED TO CONSTRUE THIS FIRST SUPPLEMENTAL INDENTURE WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW TO THE EXTENT THAT
THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION WOULD BE REQUIRED THEREBY. 
 Section 3.05 Successors. All
agreements of the Company in the Indenture, as amended by this First Supplemental Indenture, and the Notes shall bind its successors. All agreements of the Trustee in the Indenture, as amended by this First Supplemental Indenture, shall bind its
successors. All agreements of each Guarantor in the Indenture, as supplemented by this First Supplemental Indenture, shall bind its successors, except as otherwise provided in Section 11.06 of the Indenture. 
 Section 3.06 Severability. In case any provision in the Indenture, as amended by this First Supplemental Indenture, or in the
Notes is invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 
 Section 3.07 Counterpart Originals. The parties may sign any number of copies of this First Supplemental Indenture. Each signed copy shall be an original, but all of them together represent
the same agreement. 
 Section 3.08 Headings. The headings of the Articles and Sections of this First Supplemental
Indenture have been inserted for convenience of reference only, are not to be considered a part of this First Supplemental Indenture and shall in no way modify or restrict any of the terms or provisions hereof. 
 Section 3.09 Trustee’s Disclaimer. The Trustee shall not be responsible for and makes no representation as to the validity
or adequacy of this First Supplemental Indenture, and it shall not be responsible for any statement or recital herein or any other document pursuant to this First Supplemental Indenture. 
 [signature pages follow] 
  

 5 

 IN WITNESS WHEREOF, the parties hereto have caused this First Supplemental Indenture to be
duly executed and attested, all as of the date first above written. 
  

			
	JOHNSONDIVERSEY, INC.
		
	By:	 	 /s/ Joseph F. Smorada

	Name:	 	Joseph F. Smorada
	Title:	 	 Executive Vice President and
 Chief Financial Officer

	
	Guarantors:
	
	AUTO-C, LLC
		
	By:	 	 /s/ David C. Quast

	Name:	 	David C. Quast
	Title:	 	Secretary
	
	THE BUTCHER COMPANY
		
	By:	 	 /s/ David C. Quast

	Name:	 	David C. Quast
	Title:	 	Secretary
	
	DUBOIS INTERNATIONAL, INC.
		
	By:	 	 /s/ Andrew Warren

	Name:	 	Andrew Warren
	Title:	 	Assistant Secretary
	
	 INTEGRATED SANITATION MANAGEMENT, INC.

		
	By:	 	 /s/ Andrew Warren

	Name:	 	Andrew Warren
	Title:	 	Vice President & Treasurer

			
	JOHNSON DIVERSEY CAYMAN, INC.
		
	By:	 	 /s/ Andrew Warren

	Name:	 	Andrew Warren
	Title:	 	Vice President
	
	JOHNSON DIVERSEY PUERTO RICO, INC.
		
	By:	 	 /s/ Andrew Warren

	Name:	 	Andrew Warren
	Title:	 	Vice President & Treasurer
	
	JOHNSON DIVERSEY SHAREHOLDINGS, INC.
		
	By:	 	 /s/ Andrew Warren

	Name:	 	Andrew Warren
	Title:	 	Vice President & Treasurer
	
	 JOHNSON WAX DIVERSEY SHAREHOLDINGS, INC.

		
	By:	 	 /s/ Andrew Warren

	Name:	 	Andrew Warren
	Title:	 	Vice President & Treasurer
	
	JWP INVESTMENTS, INC.
		
	By:	 	 /s/ David C. Quast

	Name:	 	David C. Quast
	Title:	 	Secretary
	
	PROFESSIONAL SHAREHOLDINGS, INC.
		
	By:	 	 /s/ Andrew Warren

	Name:	 	Andrew Warren
	Title:	 	Vice President & Treasurer

			
	THE BANK OF NEW YORK MELLON, as Trustee
		
	By:	 	 /s/ Lici Zhu

	Name:	 	Lici Zhu
	Title:	 	Assistant Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}]]